Phase II development of an automated DNA sequence variation analysis software package is proposed. The software analyzes diploid DNA sequencing and mixed methylation analysis samples from phenotypically stratified patient groups. The software package detects essentially all mutations of any type, and then classifies and scores them. The goals of this Phase II are to improve upon the successful Phase I implementation and complete the originally proposed development plan. This includes automated interpretation of mutations and methylation state and association of detected mutations with a phenotypic group.

Proposed Commercial Applications

NOT AVAILABLE

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research Grants (SBIR) - Phase II (R44)
Project #
2R44CA090095-02
Application #
6485110
Study Section
Special Emphasis Panel (ZRG1-SSS-Y (10))
Program Officer
Choudhry, Jawahar
Project Start
2001-04-01
Project End
2004-04-30
Budget Start
2002-05-01
Budget End
2003-04-30
Support Year
2
Fiscal Year
2002
Total Cost
$533,126
Indirect Cost
Name
Illumigen Biosciences, Inc.
Department
Type
DUNS #
City
Seattle
State
WA
Country
United States
Zip Code
98134